AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37003355
Drug: Albuterol-budesonide 180/80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol-budesonide 180/80 μg
Trial: 37003355
Drug: Albuterol 180
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol 180 μg
Trial: 37003355
Drug: Budesonide 160
RxNorm normalized name: BUDESONIDE 160/FORMOTER 4.5MCG 60D INH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 160 μg
Trial: 37004342
Drug: Myofascial treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myofascial treatment (n = 18)
Trial: 37004599
Drug: Furmonertinib (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furmonertinib (240 mg once-daily)
Trial: 37004599
Drug: Furmonertinib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furmonertinib (80 mg once-daily)
Trial: 37004599
Drug: Furmonertinib (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furmonertinib (160 mg once-daily)
Trial: 37004656
Drug: CT-P13 SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-P13 SC monotherapy (120 or 240 mg every 2 weeks)
Trial: 37004656
Drug: CT-P13 SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-P13 SC combotherapy (with immunosuppressants)
Trial: 37004656
Drug: CT-P13 SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-P13 SC monotherapy
Trial: 37004656
Drug: CT-P13 SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-P13 SC monotherapy (in ADA-positive patients)
Trial: 37004712
Drug: lerapolturev (5 × 10)
RxNorm normalized name: Lerapolturev
DrugBank: Lerapolturev (DB17217)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lerapolturev (5 × 10) administered as a single dose intracerebrally by convection enhanced delivery
Trial: 37004712
Drug: low-dose bevacizumab
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: low-dose bevacizumab
Trial: 37004887
Drug: Methotrexate (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (combination therapy)
Trial: 37005580
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion (0.3 mg/kg bolus over 10 min, followed by 0.3 mg/kg/h infusion)
Trial: 37005580
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion (0.5 mcg/kg bolus over 10 min, followed by 0.5 mg/kg/h infusion)
Trial: 37006503
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care involving intensive supportive therapy
Trial: 37007063
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiotherapy (SABRT) at a starting dose of 40 Gy in 5 fractions
Trial: 37007572
Drug: Hyperinsulinemic normoglycemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperinsulinemic normoglycemic clamp (HNC) during surgery (insulin 2 mU/kg/min followed by 20% dextrose infusion to maintain blood glucose between 4.0 and 6.0 mmol/L until end of surgery)
Trial: 37007741
Drug: Phenotype-tailored lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenotype-tailored lifestyle intervention (PLI) with various approaches based on phenotype: time-restricted volumetric low-calorie diet, low-calorie diet with pre-meal protein supplementation, low-calorie diet with intensive behavioral therapy, low-calorie diet with post-workout protein supplementation and high-intensity interval training.
Trial: 37007741
Drug: Standard lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard lifestyle intervention (SLI) with low-calorie diet, moderate physical activity, and weekly behavioral therapy sessions.
Trial: 37007743
Drug: Thymosin alpha
RxNorm normalized name: Thymosin alpha 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin alpha 1 (Tα1) therapy
Trial: 37007788
Drug: FNC (AZVUDINE)
RxNorm normalized name: Azvudine
DrugBank: Azvudine (DB16407)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FNC (AZVUDINE) added to standard treatment
Trial: 37007788
Drug: Placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to standard treatment
Trial: 37008165
Drug: CTPS1 small
RxNorm normalized name: Smallpox vaccine
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTPS1 small molecule inhibitor
Trial: 37008891
Drug: Chin cup
RxNorm normalized name: CHIN-UP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chin cup and bonded maxillary bite block treatment
Trial: 37008942
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) and gonadotropin-releasing hormone analogue (GnRHa) for four years
Trial: 37009114
Drug: Varenicline titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline titrated to 1 mg bid, brief behavioral counseling, and TIQ texting support
Trial: 37009114
Drug: Varenicline titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline titrated to 1 mg bid
Trial: 37009425
Drug: Guajava leaf
RxNorm normalized name: PSIDIUM GUAJAVA LEAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guajava leaf treatment, specific dosage and duration not mentioned
Trial: 37009425
Drug: Various treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatments for COVID-19, including antiviral agents
Trial: 38205656
Drug: Alirocumab 150
RxNorm normalized name: alirocumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 150 mg subcutaneously every 14 days in addition to high-intensity statin therapy
Trial: 37009915
Drug: At-home serological
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At-home serological tests detecting antibodies against SARS-CoV-2 (nucleocapsid or spike antigen), conducted from 1 May 2021 to 31 October 2021.
Trial: 37010101
Drug: Neurohormonal antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neurohormonal antagonist therapy
Trial: 37010251
Drug: Goserelin implant
RxNorm normalized name: Goserelin Implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin implant
Trial: 37010549
Drug: Everolimus 5
RxNorm normalized name: everolimus 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 5 mg qd + Sorafenib 200 mg bid 5 days-on/2 days-off
Trial: 37010549
Drug: Everolimus 5
RxNorm normalized name: everolimus 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 5 mg qd + Sorafenib (standard schedule)
Trial: 37010888
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) program with digital support, 9 sessions
Trial: 37010988
Drug: Liposomal irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal irinotecan (nal-IRI) administered on days 1 and 15, and veliparib on days 5-12 and 19-25 in 28-day cycles.
Trial: 37011163
Drug: Shared decision-making
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shared decision-making (SDM) intervention; details on dosage and duration not available.
Trial: 37011163
Drug: Community participatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community participatory approaches; details on dosage and duration not available.
Trial: 37011163
Drug: Multidisciplinary, inclusive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary, inclusive research team led by a Black psychologist; details on dosage and duration not available.
Trial: 37011163
Drug: Intersectionality lens
RxNorm normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intersectionality lens applied; details on dosage and duration not available.
Trial: 37011169
Drug: Evidence-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based intervention to prevent victimization of trans women and trans femmes; details on dosage and duration not available.
Trial: 37011526
Drug: Soticlestat (≤300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soticlestat (≤300 mg/day twice daily, weight-adjusted)
Trial: 37011643
Drug: DA-EPOCH-R (six
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA-EPOCH-R (six cycles every 3 weeks of intravenous dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab)
Trial: 37011650
Drug: Belzutifan 120
RxNorm normalized name: BELZUTIFAN
DrugBank: Belzutifan (DB15463)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Belzutifan 120 mg orally once daily and cabozantinib 60 mg orally once daily until disease progression, unacceptable toxicity, or patient withdrawal.
Trial: 37011709
Drug: Valaciclovir (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valaciclovir (1 g tid for 8 weeks)
Trial: 37012015
Drug: Oral atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral atorvastatin (40 mg daily)
Trial: 37012016
Drug: 1.6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 mg/kg ilofotase alfa
Trial: 37012068
Drug: Plasma P-tau181
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma P-tau181 ≤2.32 pg/mL
Trial: 37012190
Drug: Internet-delivered Dialectical
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered Dialectical Behavior Therapy skills training
Trial: 37012306
Drug: EGb 761
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGb 761 240 mg orally, 1 tablet daily for 12 months (study group, n=50)
Trial: 37012306
Drug: EGb 761
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGb 761 240 mg orally, 1 tablet daily for an additional 12 months (after initial 12 months for control group)
Trial: 37012318
Drug: Front-line endocrine
RxNorm normalized name: Bos taurus frontal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Front-line endocrine therapy for gBRCAm carriers
Trial: 37012318
Drug: Front-line chemotherapy
RxNorm normalized name: Bos taurus frontal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Front-line chemotherapy
Trial: 37012461
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate tablets (test formulation)
Trial: 37012461
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate tablets (reference formulation)
Trial: 37012551
Drug: Lorlatinib as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib as a single agent in children (12 months to <18 years)
Trial: 37012551
Drug: Lorlatinib as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib as a single agent in adults (≥18 years)
Trial: 37012551
Drug: Lorlatinib in
RxNorm normalized name: Product containing lorlatinib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib in combination with topotecan/cyclophosphamide in children (<18 years)
Trial: 37013442
Drug: Inhaled corticosteroids/long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids/long-acting beta-agonists (ICSs/LABAs)
Trial: 37013442
Drug: Long-acting muscarinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting muscarinic antagonists (LAMAs)
Trial: 37013442
Drug: Neither ICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neither ICS nor long-acting bronchodilators
Trial: 37013610
Drug: SHR7280 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR7280 (100 to 1000 mg BID)
Trial: 37013954
Drug: Lenalidomide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (20 mg daily from days 1 to 21 of each 28-day cycle) + Rituximab (375 mg/m2 weekly, starting on cycle 1, day 1 until cycle 2, day 1) + Venetoclax (400 mg daily at maximum tolerated dose)
Trial: 37014289
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) sotalol loading dose
Trial: 37014289
Drug: Traditional oral
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional oral (PO) loading
Trial: 37014289
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) sotalol loading
Trial: 37015244
Drug: Sparsentan 400
RxNorm normalized name: sparsentan 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparsentan 400 mg once daily
Trial: 37016126
Drug: Oleclumab 5-40
RxNorm normalized name: Oleclumab
DrugBank: Oleclumab (DB15088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oleclumab 5-40 mg/kg (dose-escalation) or 40 mg/kg (dose-expansion) intravenously every 2 weeks (Q2W)
Trial: 37016126
Drug: Oleclumab 5-40
RxNorm normalized name: Oleclumab
DrugBank: Oleclumab (DB15088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oleclumab 5-40 mg/kg (dose-escalation) or 40 mg/kg (dose-expansion) intravenously every 2 weeks (Q2W) with durvalumab 10 mg/kg intravenously Q2W
Trial: 37016181
Drug: Monthly migraine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly migraine headache days
Trial: 37016303
Drug: Chemotherapy (DOS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (DOS regimen)
Trial: 37016303
Drug: Chemotherapy (DOS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (DOS regimen) after propensity score matching
Trial: 37016303
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (resection and chemotherapy)
Trial: 37016309
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol (nonspecific laxative)
Trial: 37016326
Drug: Propranolol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (20 mg oral) + Misoprostol (25 µg vaginal)
Trial: 37016326
Drug: Misoprostol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (25 µg vaginal) + Placebo
Trial: 37016392
Drug: Dihydroartemisinin-piperaquine (DP)
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine (DP) - weekly single-day courses
Trial: 37016392
Drug: Sulphadoxine-pyrimethamine (SP)
RxNorm normalized name: pyrimethamine / sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphadoxine-pyrimethamine (SP) - monthly single-day courses
Trial: 37016394
Drug: MOUD with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOUD with adjunctive use of OptiMAT (MOUD+OptiMAT)
Trial: 37016469
Drug: Longest daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longest daily sustained walking bout at 1-19 steps
Trial: 37016906
Drug: Osimertinib 80
RxNorm normalized name: osimertinib 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib 80 mg oral daily and bevacizumab 15 mg/kg intravenously on day 1, repeated every 21 days until disease progression, intolerable toxicity, or death
Trial: 37017254
Drug: Belimumab plus
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Belimumab plus standard therapy (ST)
Trial: 37017254
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (ST) alone
Trial: 37018064
Drug: Vorinostat (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorinostat (oral administration)
Trial: 37018188
Drug: Tapering doses
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapering doses of prednisone
Trial: 37018188
Drug: Cumulative glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative glucocorticoid doses
Trial: 37018234
Drug: Busulfan treatment
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan treatment in lymphoblastoid cell lines (LCLs)
Trial: 37018234
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of expression experiment and WES data analysis
Trial: 37018415
Drug: Chimeric antigen
RxNorm normalized name: Chimeric antigen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric antigen receptor (CAR)-T cells enriched in memory T cells
Trial: 37018468
Drug: RSVpreF vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVpreF vaccine (120 μg)
Trial: 37018474
Drug: Bivalent RSV
RxNorm normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent RSV prefusion F protein-based vaccine (120 μg, single intramuscular injection)
Trial: 37018649
Drug: Fluorouracil and
RxNorm normalized name: Fluorouracil and salicylic acid only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil and folinic acid maintenance therapy with panitumumab
Trial: 37018649
Drug: Fluorouracil and
RxNorm normalized name: Fluorouracil and salicylic acid only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil and folinic acid maintenance therapy without panitumumab
Trial: 37018790
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg once daily for 14 days
Trial: 37019077
Drug: ARB dose
RxNorm normalized name: revakinagene taroretcel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB dose >0%-25%
Trial: 37019077
Drug: ARB dose
RxNorm normalized name: revakinagene taroretcel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB dose >25%
Trial: 37019077
Drug: ARB dose
RxNorm normalized name: revakinagene taroretcel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB dose ≤25%
Trial: 37019334
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose erythropoietin (Epo)
Trial: 37019367
Drug: Nivolumab and
RxNorm normalized name: nivolumab and relatlimab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab and Ipilimumab with Definitive Radiation Therapy
Trial: 37019443
Drug: 1 g IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g IV tranexamic acid (TXA)
Trial: 37019443
Drug: 1 g IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g IM tranexamic acid (TXA)
Trial: 37019443
Drug: 4 g oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g oral tranexamic acid (TXA)
Trial: 37019619
Drug: Anti-PD-L1 therapy
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Anti-PD-L1 therapy
Trial: 37019821
Drug: RhoA/Rho-kinase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RhoA/Rho-kinase inhibitor (fasudil)
Trial: 37020805
Drug: Docosahexaenoic acid
RxNorm normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docosahexaenoic acid (DHA) supplementation at 500 mg/day
Trial: 37020837
Drug: Physiological assessments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological assessments of pulmonary function including spirometry, bronchodilator reversibility, static lung volumes
Trial: 37020840
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg d-cycloserine
Trial: 37021170
Drug: Standardized educational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized educational talk (SET) on intravenous thrombolysis (IVT)
Trial: 37021342
Drug: Rise of
RxNorm normalized name: TITANIUM DIOXIDE 20 mg in 1 g TOPICAL STICK [Flormar Delicious Lip Stylo Sunscreen Broad Spectrum SPF 15 DS14 Rise of Modern City]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rise of >5 bpm in weekly average NHR
Trial: 37021397
Drug: Alemtuzumab administered
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alemtuzumab administered intravenously (IV)
Trial: 37021397
Drug: Alemtuzumab administered
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alemtuzumab administered subcutaneously (SC)
Trial: 37021546
Drug: Polyethylene glycol-coated
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol-coated haemostatic patch (patch group)
Trial: 37021629
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 mL 0.9% saline and oral simulation capsule)
Trial: 37021692
Drug: Cessation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cessation of treatment
Trial: 37022502
Drug: Cognitive Restructuration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Restructuration Treatment Group (CRTG, n=13)
Trial: 37022702
Drug: Metastasis-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metastasis-directed therapy (MDT) with intermittent hormone therapy (combined therapy arm; n=43)
Trial: 37022702
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy only (n=44)
Trial: 37022706
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus ipilimumab (3 mg/kg IV every 2 weeks plus 1 mg/kg IV every 6 weeks)
Trial: 37022717
Drug: Cyclosporine solution,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine solution, 0.1%, applied twice daily for 29 days
Trial: 37022717
Drug: Vehicle, applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle, applied twice daily for 29 days